Stage IV Salivary Gland Cancer Completed Phase 1 Trials for Cetuximab (DB00002)

Also known as: Salivary gland cancer stage IV / Metastatic salivary gland cancer / Malignant salivary gland cancer stage IV

IndicationStatusPhase
DBCOND0028780 (Stage IV Salivary Gland Cancer)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00397384Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerTreatment
NCT01334177TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and NeckTreatment